New research at the School of Medicine indicates that initial levels of omega-3 fatty acids in a heart patient’s blood have a significant impact on whether that person will respond to omega-3 supplements to treat depression.
Researchers at the School of Medicine are studying the quality, effectiveness and safety of generic drugs used to treat depression. The research, supported by the U.S. Food and Drug Administration, is the only study of its kind in the nation. Pictured is the study’s principal investigator, Evan D. Kharasch, MD, PhD.
A study of older adults has found that combining antidepressants with cognitive behavioral therapy appears to be effective as a treatment for anxiety. Pictured is Eric J. Lenze, MD, professor of psychiatry, discussing therapy options with Diana Simpson.
Washington University School of Medicine has opened a clinic for patients with treatment-resistant depression that targets those who haven’t responded to standard therapies. When at least two therapies have been tried, and a patient still hasn’t responded, that patient is said to have treatment-resistant depression, according to clinic director Charles R. Conway, MD.
Researchers at Washington University School of Medicine in St. Louis are studying people age 60 and older to determine whether augmenting medication for depression with a second drug might help older patients break free of clinical depression. Both study drugs are FDA-approved therapies for depression in younger adults, but the benefits need to be examined in older adults.